Article Text

Download PDFPDF
Letter
Letter to the editor regarding the report of Duboc et al: connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease
  1. Mitchell L Jones1,2,
  2. Christopher J Martoni2,
  3. Satya Prakash1,2
  1. 1Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering, McGill University, Montreal, Quebec, Canada
  2. 2Micropharma Limited, Montreal, Quebec, Canada
  1. Correspondence to Professor Satya Prakash, Biomedical Technology and Cell Therapy Research Laboratory, Department of Biomedical Engineering and Physiology, Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, 3775 University Street, Montreal, QC, Canada H3A 2B4; satya.prakash{at}mcgill.ca

Statistics from Altmetric.com

We read with interest the informative and required investigation of bile-acid dysmetabolism, dysbiosis and inflammation in inflammatory bowel diseases (IBD) by Duboc et al.1 The paper suggests that a characteristic finding of IBD is reduced faecal secondary bile acids (BA), increased conjugated BA and increased sulphated BA.1 The authors link the luminal dysmetabolism of BA to dysbiosis, and the loss of microbiota deconjugation, transformation and desulphation enzymatic functions.1 The authors report convincing evidence demonstrating that a decrease in bacteria-bearing bile salt hydrolase (BSH) activities may be involved in the increase in conjugated BA remaining in the faeces, and show that germ-free mice have a similar loss of microbiota enzymatic function and display similar faecal BA irregularities.1 In addition to their role in dietary lipid absorption, BA are signalling modules activating nuclear receptors, including the farnesoid-X-receptor, the constitutive androstane receptor, the pregnane-X-receptor and the vitamin D receptor (VDR), as well as the …

View Full Text

Footnotes

  • Contributors MLJ, SP and CJM designed the study and prepared the letter. All authors have read and approved the final manuscript.

  • Funding This work was supported by Micropharma Limited.

  • Competing interests MLJ and SP acknowledge a conflict of interest as they are cofounders and shareholders of Micropharma. CJM is employed by, and is a shareholder of, Micropharma.

  • Patient consent Obtained.

  • Ethics approval The study was conducted according to the principles of the Declaration of Helsinki. Otherwise healthy hypercholesterolemic adults were recruited from six centres in Prague, Czech Republic. The protocol was approved by the Ethics Committee for multicentric clinical trials of the University Hospital Motol, Czech Republic (FDA/OHRP IORG registration no. IORG0000612). The trial was registered on www.clinicaltrials.gov under study number NCT01341613.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Inflammatory bowel disease
    Henri Duboc Sylvie Rajca Dominique Rainteau David Benarous Marie-Anne Maubert Elodie Quervain Ginette Thomas Véronique Barbu Lydie Humbert Guillaume Despras Chantal Bridonneau Fabien Dumetz Jean-Pierre Grill Joëlle Masliah Laurent Beaugerie Jacques Cosnes Olivier Chazouillères Raoul Poupon Claude Wolf Jean-Maurice Mallet Philippe Langella Germain Trugnan Harry Sokol Philippe Seksik